Abnormal activation of the
nuclear factor-kappa B (NF-κB) signaling pathway is closely implicated in
triple-negative breast cancer growth,
metastasis, and tumor immune escape. In this study, the anti-
cancer effects of
icariin, a natural
flavonol glycoside, toward
breast cancer cells and the underlying mechanisms were investigated. This investigation showed that
icariin selectively inhibited proliferation and triggered apoptosis in
breast cancer cells in a concentration- and time-dependent manner, but exhibited little cytotoxicity in normal breast cells. Moreover,
icariin induced cell apoptosis via a mitochondria-mediated pathway, as indicated by the upregulated ratio of Bax/Bcl-2 and
reactive oxygen species induction. Importantly,
icariin impaired the activation of the NF-κB/EMT pathway, as evidenced by upregulation of SIRT6, resulting in inhibition of migration and invasion of
breast cancer cells. Additionally, oss-128167, an inhibitor of SIRT6, dramatically attenuated anti-migration and anti-invasion effects of
icariin. Transcriptomic analysis verified that impairment of NF-κB led to the selective function of
icariin in
breast cancer cells. Notably,
icariin exhibited a significant
tumor growth inhibition and anti-pulmonary
metastasis effect in a
tumor mouse model of MDA-MB-231 and 4T1 cells by regulating the
tumor immunosuppressive microenvironment. Together, these results showed that
icariin could effectively trigger apoptosis and inhibit the migration of
breast cancer cells via the SIRT6/NF-κB signaling pathway, suggesting that
icariin might serve as a potential candidate drug for the treatment of
breast cancer.